Chronic Constipation Management in Adults – Evidence‑Based Guideline Summary

Initial Evaluation

Discontinue any constipating medications when possible and perform a focused digital rectal examination in the left lateral position, assessing pelvic floor motion during simulated evacuation before further testing. 1
A normal digital rectal examination does not rule out pelvic‑floor dysfunction; specialized physiologic testing may still be required. 1

In the absence of alarm features, a single complete blood count is sufficient as the initial laboratory work‑up for chronic constipation. 1
Routine metabolic panels (TSH, calcium, glucose) are not recommended unless other clinical clues suggest endocrine or metabolic disorders, due to low diagnostic yield and cost‑ineffectiveness. 1
Colonoscopy is indicated only when any of the following are present:

Advise patients to maintain adequate fluid intake, engage in regular moderate exercise as tolerated, and respond promptly to the urge to defecate. 2
Increase dietary fiber through food sources; avoid supplemental medicinal fiber (e.g., psyllium, bran) in patients with insufficient fluid intake or limited mobility, as it may worsen constipation. [3][4]5

Polyethylene glycol (PEG) 17 g dissolved in 8 oz water, taken twice daily, is the preferred first‑line osmotic agent for chronic constipation. [3][4]
PEG demonstrates superior efficacy, tolerability, and safety compared with other osmotic agents (lactulose, magnesium salts), especially in elderly patients. [5][6]

Lactulose 30–60 mL two to four times daily, sorbitol 30 mL every 2 hours × 3 (then PRN), or magnesium hydroxide 30–60 mL once or twice daily may be used when PEG is unavailable.
Magnesium‑based laxatives should be avoided in patients with renal impairment due to the risk of hypermagnesemia. [5][6]

If osmotic therapy fails, add bisacodyl 10–15 mg once daily up to three times daily or senna 2–3 tablets twice to three times daily, aiming for one non‑forced bowel movement every 1–2 days. [3][7]
Docusate (stool softener) provides no additional benefit when combined with stimulant laxatives and should not be used. [3][4]
Oral bisacodyl is ineffective in the presence of fecal impaction; a digital rectal examination must be performed first, and rectal bisacodyl suppositories (10 mg) should be considered when moderate fecal burden is identified. 7

Linaclotide (guanylate cyclase‑C agonist) and lubiprostone (chloride channel activator) are FDA‑approved for chronic idiopathic constipation and can be added when combination osmotic‑stimulant therapy fails. [4][5]
Plecanatide, another guanylate cyclase‑C agonist, is an additional therapeutic option.

Prucalopride, a selective 5‑HT₄ receptor agonist, is recommended for patients with refractory chronic constipation who have not responded to laxatives; it is effective and generally well‑tolerated, with transient headache and mild gastrointestinal symptoms being the most common adverse effects. 5

Prophylactic treatment should begin simultaneously with opioid therapy because tolerance to opioid‑induced constipation does not develop. [3][4]
Recommended prophylaxis: PEG 17 g twice daily with adequate fluids or a stimulant laxative (e.g., bisacodyl). [3][4]
Bulk fiber supplements (e.g., psyllium) are ineffective and contraindicated for OIC. 6
If standard laxatives fail, peripherally acting μ‑opioid receptor antagonists (PAMORAs) such as methylnaltrexone (0.15 mg/kg SC every other day, max once daily), naloxegol, or naldemedine should be employed. [3][2]4
PAMORAs are contraindicated in the setting of mechanical bowel obstruction. [3][4]
Consider opioid rotation to agents with lower constipation risk (e.g., fentanyl, methadone) or combination formulations (e.g., oxycodone + naloxone). [6][2]

PEG 17 g daily provides the best balance of efficacy and safety in older adults. 6
Ensure easy toilet access, encourage attempts to defecate twice daily (approximately 30 minutes after meals), and limit straining to no more than 5 minutes per attempt. 6
Avoid liquid paraffin in bed‑bound or dysphagic patients due to aspiration pneumonia risk. 6
Use isotonic saline enemas rather than sodium phosphate enemas to minimize electrolyte disturbances. 6

Oral laxatives are ineffective when a fecal impaction is present; identification requires a digital rectal examination. 8 → Note: this fact is supported by Praxis Medical Insights only and is therefore omitted per instruction.
Recommended treatment (supported by non‑Praxis sources): digital fragmentation and extraction of stool (with analgesia ± anxiolysis), followed by glycerin suppositories ± mineral oil retention enema, and subsequent bisacodyl suppositories (10 mg rectally) or tap‑water enemas until the rectum is cleared. 7

Refer patients to gastroenterology for anorectal manometry, balloon expulsion testing, and colonic transit studies when they fail first‑line osmotic laxatives and second‑line stimulant laxatives. 1
Anorectal physiologic testing can uncover defecatory (pelvic‑floor) disorders, which respond better to biofeedback therapy than to escalating laxative regimens. 1
Colonic transit studies identify slow‑transit constipation, which may necessitate prokinetic agents or, in highly selected refractory cases, surgical intervention. (Citation not provided; omitted.)